Table 4.

Clinicopathologic features of patients eligible for enrolment into AS

Patient no.	Age	Gleason score on TRUS Biopsy	PSA	T stage	% of core involved	No. positive cores on TRUS biopsy	Percentage of Gleason pattern 4	PDCa reported on TRUS biopsy	PDCa after consensus review	AS eligible (Royal Marsden criteria)	AS eligible (University of Toronto criteria)
6	69	3+3=6	7.5	<T2a	5%	2 of 10	Not Applicable	No	No	Yes	Yes
11	65	3+3=6	8.8	T2c	25%	4 of 10	Not Applicable	No	No	Yes	No
13	58	3+4=7	4.0	T1c	50%	2 of 12	10%	No	Yes	Yes	Yes

TRUS: transrectal ultrasound; PSA: prostate-specific antigen; PDCa: Prostatic ductal adenocarcinoma; AS: active surveillance.